Work

Supplemental Figure 3 from The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer

Year: 2023

Type: supplementary-materials

Abstract: Supplemental Figure 3. Effect of the combination of YAP1 inhibitor VP, EGFR inhibitor Erlotinib and 5-FU on EC cell growth

DOI: 10.1158/1078-0432.22459349.v1

Authors: Shumei Song, Soichiro Honjo, Jiankang Jin, Shih-Shin Chang, Ailing W. Scott, Qiongrong Chen, Neda Kalhor, Arlene M. Correa, Wayne L. Hofstetter, Constance T. Albarracin, Tsung-Teh Wu, Randy L. Johnson, Mien-Chie Hung, Jaffer A. Ajani

Language: English

Topic: Hippo pathway signaling and YAP/TAZ

Subfield: Cell Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361918558

Cites:

Cited by:

Related to: 10